Heinicke, Thomas, Labopin, Myriam, Polge, Emmanuelle, Stelljes, Matthias, Ganser, Arnold, Tischer, Johanna, Brecht, Arne, Kroger, Nicolaus, Beelen, Dietrich W., Scheid, Christof, Bethge, Wolfgang, Dreger, Peter, Bunjes, Donald, Wagner, Eva, Platzbecker, Uwe, Savani, Bipin N., Nagler, Arnon and Mohty, Mohamad . Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT. Leuk. Lymphoma. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Full text not available from this repository.

Abstract

The Acute Leukemia Working Party (ALWP) of the EBMT assessed the outcome of allogeneic stem cell transplantation (alloSCT) in patients with relapsed/refractory AML (r/rAML) evaluating six sequential conditioning regimens (SR) groups. A total of 2132 patients were included. LFS at 2 years was 28.9%, 33.6%, 35.3%, 20.6%, 24.4%, and 27% for the FLAMSA-TBI4, FLAMSA-Chemo, Mel-Flu-TBI8, Mel-Treo-Flu, Thio-ETO-Cy-Bu2-Flu, and Clo-ARAC-(Bu2/TBI4)-Cy groups, respectively. In patients <55 years of age Mel-Flu-TBI8 had the best LFS, which was statistically significant only in comparison to the Mel-Treo-Flu group, while in patients >= 55 years LFS was best with FLAMSA-Chemo without significant differences compared to FLAMSA-TBI4 and Mel-Flu-TBI8. Furthermore, best NRM rates were obtained with the two FLAMSA regimens groups. Our study suggests that in younger (<55 years) patients a more intense regimen might be used whereas in older (>= 55 years) patients the focus might be more on tolerability.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Heinicke, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Labopin, MyriamUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Polge, EmmanuelleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stelljes, MatthiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ganser, ArnoldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tischer, JohannaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brecht, ArneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kroger, NicolausUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beelen, Dietrich W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheid, ChristofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bethge, WolfgangUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dreger, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bunjes, DonaldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wagner, EvaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Platzbecker, UweUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Savani, Bipin N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nagler, ArnonUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mohty, MohamadUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-315304
DOI: 10.1080/10428194.2020.1827248
Journal or Publication Title: Leuk. Lymphoma
Publisher: TAYLOR & FRANCIS LTD
Place of Publication: ABINGDON
ISSN: 1029-2403
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ACUTE MYELOID-LEUKEMIA; VERSUS-HOST-DISEASE; HIGH-DOSE MELPHALAN; HIGH-RISK; ADULT PATIENTS; SALVAGE THERAPY; EUROPEAN GROUP; OLDER PATIENTS; AML; RELAPSEMultiple languages
Oncology; HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/31530

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item